Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Brain and spinal cord tumours (all types), drawn from the whole corpus: 45 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Drugs rarely cross the blood-brain barrier at useful concentrations.
Diffuse midline glioma remains almost uniformly fatal.
Cognitive late effects of radiotherapy in children.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 22 changes by month →When this page itself was last checked or edited.
Three-year progression-free survival 78 percent after high-dose chemotherapy and autologous transplant against 51 percent after non-myeloablative R-DeVIC (hazard ratio 0.
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.
Brigatinib produced radiographic responses in 10 percent of target tumours and 23 percent of all tumours, slowed growth of every tumour type and improved hearing in 35 percent of eligible ears in 40 heavily pretreated patients.
First targeted drug for grade 2 astrocytoma and oligodendroglioma after surgery (INDIGO trial).
Hazard of an event 0.